Abstract
Irinotecan has been increasingly used for treatment of pediatric cancers over the past decade. Irinotecan has modest single-agent activity against common childhood solid tumors, and the low incidence of myelosuppression seen with protracted administration makes it well-suited for combination chemotherapy regimens. Data from mouse xenograft models and clinical trials suggest the activity of irinotecan can be improved by the addition of temozolomide, vincristine, or bevacizumab. These observations have led to focused investigation in at least seven different types of childhood cancer. This report summarizes the progress made in understanding the spectrum of activity, pharmacokinetics, pharmacogenetics, toxicity profile, and mechanisms of resistance of this agent. Also reviewed are the different schedules and routes of administration that have been investigated in pediatric clinical trials. Finally, potential applications for future use are discussed, including novel combinations with targeted therapies.
Keywords: Irinotecan, pediatric cancer, neuroblastoma, Ewing sarcoma, rhabdomyosarcoma.
Current Cancer Therapy Reviews
Title:Irinotecan for Treatment of Childhood Cancers: A Promising Therapeutic Partner
Volume: 6 Issue: 4
Author(s): Lars Wagner
Affiliation:
Keywords: Irinotecan, pediatric cancer, neuroblastoma, Ewing sarcoma, rhabdomyosarcoma.
Abstract: Irinotecan has been increasingly used for treatment of pediatric cancers over the past decade. Irinotecan has modest single-agent activity against common childhood solid tumors, and the low incidence of myelosuppression seen with protracted administration makes it well-suited for combination chemotherapy regimens. Data from mouse xenograft models and clinical trials suggest the activity of irinotecan can be improved by the addition of temozolomide, vincristine, or bevacizumab. These observations have led to focused investigation in at least seven different types of childhood cancer. This report summarizes the progress made in understanding the spectrum of activity, pharmacokinetics, pharmacogenetics, toxicity profile, and mechanisms of resistance of this agent. Also reviewed are the different schedules and routes of administration that have been investigated in pediatric clinical trials. Finally, potential applications for future use are discussed, including novel combinations with targeted therapies.
Export Options
About this article
Cite this article as:
Wagner Lars, Irinotecan for Treatment of Childhood Cancers: A Promising Therapeutic Partner, Current Cancer Therapy Reviews 2010; 6 (4) . https://dx.doi.org/10.2174/157339410793358110
DOI https://dx.doi.org/10.2174/157339410793358110 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances in Psoriasis Therapy: Trends and Future Prospects
Current Drug Targets Is there a Role for Bevacizumab in Non-Glial Tumors?
Current Drug Targets 1,2,3-Triazine Scaffold as a Potent Biologically Active Moiety: A Mini Review
Mini-Reviews in Medicinal Chemistry Recent Techniques Used in Reproductive Medicine: Outcomes for Gametes Manipulation
Current Women`s Health Reviews Electrostatic Potential Energy in Protein-Drug Complexes
Current Medicinal Chemistry Expression of mTOR/70S6K Signaling Pathway in Melanoma Cancer Cells and the Effects of Dacarbazine and Metformin
Current Cancer Therapy Reviews Effect of Neuroinflammation on ABC Transporters: Possible Contribution to Refractory Epilepsy
CNS & Neurological Disorders - Drug Targets Genetics and Mitochondrial Abnormalities in Autism Spectrum Disorders:A Review
Current Genomics Adverse Reactions Induced by Minocycline: A Review of Literature
Current Drug Safety Molecularly Guided Therapy of Neuroblastoma: A Review of Different Approaches
Current Pharmaceutical Design Isolated Mitochondrial Complex I Deficiency: Explorative Data Analysis of Patient Cell Parameters
Current Pharmaceutical Design Prophylactic Vaccine Approach for Colon and Pancreatic Cancers: Present and Future
Current Medicinal Chemistry The Inhibitor of Growth (ING) Gene Family: Potential Role in Cancer Therapy
Current Cancer Drug Targets New Insights into HLA-G and Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Never Sleep with Baby? Or Keep Me Close But Keep Me Safe: Eliminating Inappropriate “Safe Infant Sleep” Rhetoric in the United States
Current Pediatric Reviews Non-Celiac Gluten Sensitivity Triggers Gut Dysbiosis, Neuroinflammation, Gut-Brain Axis Dysfunction, and Vulnerability for Dementia
CNS & Neurological Disorders - Drug Targets Vitamin D Deficiency and Acute Lung Injury
Inflammation & Allergy - Drug Targets (Discontinued) Thiopurines in Inflammatory Bowel Disease - The Role of Pharmacogenetics and Therapeutic Drug Monitoring
Current Pharmacogenomics Effect of DNA Repair Deficiencies on the Cytotoxicity of Drugs Used in Cancer Therapy - A Review
Current Medicinal Chemistry Novel Insights Into the Role of MicroRNA in Lung Cancer Resistance to Treatment and Targeted Therapy
Current Cancer Drug Targets